230962-37-5Relevant academic research and scientific papers
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers
Fray, M. Jonathan,Dickinson, Roger P.,Huggins, John P.,Occleston, Nicholas L.
, p. 3514 - 3525 (2007/10/03)
The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col
Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif
Ashcroft, Christopher P.,Challenger, Stephen,Derrick, Andrew M.,Storey, Richard,Thomson, Nicholas M.
, p. 362 - 368 (2013/09/06)
An efficient and practical synthesis is presented of the pharmaceutically active MMP-3 inhibitor UK-370,106 (1) via an olefination/catalytic asymmetric hydrogenation sequence. Commercially available 5-bromo-2-iodotoluene was converted in two steps to the
Novel olefination process to itaconate and succinate derivatives
-
, (2008/06/13)
An efficient and selective process, capable of scale-up, to make itaconate derivatives of formula (IV), and/or succinate derivatives of formula (V) and/or (VI) by asymmetric hydrogenation of the itaconate derivatives.
Matrix metalloprotease inhibitors
-
, (2012/04/23)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors
